Pfizer Inc., will pay $409.9 million for illegally marketing the kidney transplant drug Rapamune, according to the U.S. Justice Department. Pfizer, which acquired Wyeth Pharmaceuticals in 2009, trained its sales force to promote the drug for unapproved uses in order to boost sales with little regard for the health and safety of “a highly vulnerable patient population dependent on life-sustaining therapy,” says Antionette Henry, Food and Drug Administration (FDA) Agent in Charge. Rapamune was approved by the FDA in 1999 for kidney transplant patients to help keep the immune system from rejecting the new organ. Wyeth pushed its sales team ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.